Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Cancer Research Communications
|
March 27, 2023
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, et al.
British Journal of Haematology
|
January 9, 2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Simon E Richardson, Iftekhar Khan, Andrew Rawstron, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Sara Bringhen, Luděk Pour, Reuben Benjamin, et al.
Cancer Research Communications
|
March 6, 2023
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Ana M Metelo, Agnieszka Jozwik, Le Anh Luong, et al.
Frontiers in Immunology
|
February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, Qatar
Bella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
The Lancet. Haematology
|
October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Reuben Benjamin, Nitin Jain, Marcela V Maus, et al.
British Journal of Haematology
|
March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
The Lancet. Haematology
|
December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Kwee Yong, William Wilson, Ruth M de Tute, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet Regional Health. Europe
|
May 13, 2026
A roadmap for supporting the development of advanced therapy medicinal products in a European framework
Johan Van Eldere, Alessandro Aiuti, Silvia Martin Lluesma, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Cancer Research Communications
|
March 27, 2023
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, et al.
British Journal of Haematology
|
January 9, 2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Simon E Richardson, Iftekhar Khan, Andrew Rawstron, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Sara Bringhen, Luděk Pour, Reuben Benjamin, et al.
Cancer Research Communications
|
March 6, 2023
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Ana M Metelo, Agnieszka Jozwik, Le Anh Luong, et al.
Frontiers in Immunology
|
February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, Qatar
Bella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
The Lancet. Haematology
|
October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Reuben Benjamin, Nitin Jain, Marcela V Maus, et al.
British Journal of Haematology
|
March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
The Lancet. Haematology
|
December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Kwee Yong, William Wilson, Ruth M de Tute, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet Regional Health. Europe
|
May 13, 2026
A roadmap for supporting the development of advanced therapy medicinal products in a European framework
Johan Van Eldere, Alessandro Aiuti, Silvia Martin Lluesma, et al.
Page
of 5